vs
Axsome Therapeutics, Inc.（AXSM）与PATHWARD FINANCIAL, INC.（CASH）财务数据对比。点击上方公司名可切换其他公司
PATHWARD FINANCIAL, INC.的季度营收约是Axsome Therapeutics, Inc.的1.4倍（$276.3M vs $191.2M），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs 21.0%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
AXSM vs CASH — 直观对比
营收规模更大
CASH
是对方的1.4倍
$191.2M
两年增速更快
AXSM
近两年复合增速
21.0%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $191.2M | $276.3M |
| 净利润 | — | $72.9M |
| 毛利率 | — | — |
| 营业利润率 | -33.1% | — |
| 净利率 | — | 26.4% |
| 营收同比 | 57.4% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $3.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMCASH
| Q1 26 | $191.2M | $276.3M | ||
| Q4 25 | $196.0M | $173.1M | ||
| Q3 25 | $171.0M | $186.7M | ||
| Q2 25 | $150.0M | $195.8M | ||
| Q1 25 | $121.5M | $274.8M | ||
| Q4 24 | $118.8M | $182.6M | ||
| Q3 24 | $104.8M | $179.5M | ||
| Q2 24 | $87.2M | $188.6M |
净利润AXSMCASH
| Q1 26 | — | $72.9M | ||
| Q4 25 | $-28.6M | $35.2M | ||
| Q3 25 | $-47.2M | $38.8M | ||
| Q2 25 | $-48.0M | $42.1M | ||
| Q1 25 | $-59.4M | $75.0M | ||
| Q4 24 | $-74.9M | $30.0M | ||
| Q3 24 | $-64.6M | $33.5M | ||
| Q2 24 | $-79.3M | $44.9M |
营业利润率AXSMCASH
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 24.6% | ||
| Q3 25 | -27.0% | 25.9% | ||
| Q2 25 | -24.5% | 24.1% | ||
| Q1 25 | -46.9% | 33.2% | ||
| Q4 24 | -61.1% | 19.8% | ||
| Q3 24 | -59.8% | 20.9% | ||
| Q2 24 | -89.5% | 27.1% |
净利率AXSMCASH
| Q1 26 | — | 26.4% | ||
| Q4 25 | -14.6% | 20.3% | ||
| Q3 25 | -27.6% | 20.8% | ||
| Q2 25 | -32.0% | 21.5% | ||
| Q1 25 | -48.9% | 27.3% | ||
| Q4 24 | -63.1% | 16.4% | ||
| Q3 24 | -61.7% | 18.7% | ||
| Q2 24 | -91.0% | 23.8% |
每股收益（稀释后）AXSMCASH
| Q1 26 | — | $3.35 | ||
| Q4 25 | $-0.55 | $1.57 | ||
| Q3 25 | $-0.94 | $1.69 | ||
| Q2 25 | $-0.97 | $1.81 | ||
| Q1 25 | $-1.22 | $3.14 | ||
| Q4 24 | $-1.54 | $1.23 | ||
| Q3 24 | $-1.34 | $1.34 | ||
| Q2 24 | $-1.67 | $1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $305.1M | $157.6M |
| 总债务越低越好 | $70.0M | $59.5M |
| 股东权益账面价值 | — | $850.7M |
| 总资产 | $713.6M | $7.1B |
| 负债/权益比越低杠杆越低 | — | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资AXSMCASH
| Q1 26 | $305.1M | $157.6M | ||
| Q4 25 | $322.9M | $331.2M | ||
| Q3 25 | $325.3M | $120.6M | ||
| Q2 25 | $303.0M | $258.3M | ||
| Q1 25 | $300.9M | $254.2M | ||
| Q4 24 | $315.4M | $597.4M | ||
| Q3 24 | $327.3M | $158.3M | ||
| Q2 24 | $315.7M | $298.9M |
总债务AXSMCASH
| Q1 26 | $70.0M | $59.5M | ||
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $33.5M | ||
| Q2 25 | — | $33.4M | ||
| Q1 25 | — | $33.4M | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | — | $33.3M |
股东权益AXSMCASH
| Q1 26 | — | $850.7M | ||
| Q4 25 | $88.3M | $854.5M | ||
| Q3 25 | $73.7M | $858.0M | ||
| Q2 25 | $73.1M | $819.0M | ||
| Q1 25 | $53.2M | $814.7M | ||
| Q4 24 | $57.0M | $758.3M | ||
| Q3 24 | $92.9M | $822.5M | ||
| Q2 24 | $102.9M | $748.4M |
总资产AXSMCASH
| Q1 26 | $713.6M | $7.1B | ||
| Q4 25 | $689.8M | $7.6B | ||
| Q3 25 | $669.3M | $7.2B | ||
| Q2 25 | $639.8M | $7.2B | ||
| Q1 25 | $596.7M | $7.0B | ||
| Q4 24 | $568.5M | $7.6B | ||
| Q3 24 | $561.5M | $7.5B | ||
| Q2 24 | $548.2M | $7.5B |
负债/权益比AXSMCASH
| Q1 26 | — | 0.07× | ||
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
